SCHEMBL6284606

SCHEMBL6284606

Cc1cccc(C)c1NC(=O)CN1CCN(C[C@H](O)COc2ccc3oc(-c4ccccc4Cl)nc3c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.63
CYP2D6 P10635 1/20 0.54
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
ADRB2 P07550 1/20 0.54
ADRB1 P08588 1/20 0.54
ADRA2A P08913 1/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
ADRA1A P35348 1/20 0.54
DRD3 P35462 1/20 0.54
HTR2B P41595 1/20 0.54
KCNH2 Q12809 1/20 0.54
SCN5A Q14524 1/20 0.54
LMNA P02545 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286713 1.00 CYP3A4 (0.63) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL6702622 0.93 CYP3A4 (0.54) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL6702627 0.90 CYP3A4 (0.52) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL6286309 0.90 CYP3A4 (0.52) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL6281596 0.90 CYP3A4 (0.52) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL5228644 0.89 CYP3A4 (0.66) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL6283483 0.89 CYP3A4 (0.60) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL5227893 0.87 CYP3A4 (0.71) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL5224706 0.84 CYP3A4 (0.61) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL6283749 0.84 CYP3A4 (0.57) CYP3A4CYP2D6TSHRNFKB1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849632-B2 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. (US) 2005-02-01 US disclosed
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ZABLOCKI JEFF (US) 2004-09-30 US disclosed
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 CYP3A4 2560/4885CYP2D6 1098/4885TSHR 4265/4885
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 CYP3A4 2560/4885CYP2D6 1098/4885TSHR 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.